CIRCULATION-ARRHYTHMIA AND ELECTROPHYSIOLOGY, vol.10, no.1, 2017 (SCI-Expanded)
Article / Article
CIRCULATION-ARRHYTHMIA AND ELECTROPHYSIOLOGY
Science Citation Index Expanded (SCI-EXPANDED), Scopus
atrial fibrillation, bleeding, mortality, stroke, thromboembolism, ASSOCIATION TASK-FORCE, AMERICAN-COLLEGE, WARFARIN, MANAGEMENT, COLLABORATION, PERSISTENT, GUIDELINES, EDOXABAN, UPDATE
Gazi University Affiliated:
Background-Whether the pattern of atrial fibrillation (AF) modifies the risk/benefit of anticoagulation is controversial. In ENGAGE AF-TIMI 48 trial (Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48), the factor Xa inhibitor edoxaban was noninferior to warfarin in preventing stroke or systemic embolic events and significantly reduced bleeding and cardiovascular mortality. However, detailed analyses by AF pattern have not been reported.